

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Link-Asia International MedTech Group Limited**

**環亞國際醫療科技集團有限公司**

*(incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1143)**

**UPDATE ON DELAY IN DESPATCH OF ANNUAL REPORT  
FOR THE YEAR ENDED 31 DECEMBER 2021**

Reference is made to the announcement of Link-Asia International MedTech Group Limited (the “**Company**”) dated 30 March 2022 (the “**Announcement**”) in relation to the unaudited results announcement for the year ended 31 December 2021. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, the Company’s auditing process for the year ended 31 December 2021 has been disrupted due to the implementation of the COVID-19 pandemic prevention and control quarantine measures in certain cities in the PRC. Such arrangements included allowing Shenzhen office staffs, Hong Kong office staffs and auditors to take turns to work from home. In recently, due to the surge of COVID-19 cases and prolonged lockdown of Shanghai in the PRC, the management of the Company has affected by the travel restrictions and quarantine measures.

The board of directors (“**Board**”) wishes to update shareholders and potential investors of the Company that, as at the date of this announcement, the lockdown in Shanghai has not been fully released. As such, the Board has therefore resolved to postpone to despatch of the 2021 Annual Report on 3 May 2022.

Further announcement(s) will be made by the Company as and when necessary.

By Order of the Board  
**Link-Asia International MedTech Group Limited**  
**Lin Dailian**  
*Chairman and Executive Director*

Hong Kong, 3 May 2022

*As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.*